NCT02270944 - Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine | Biotech Hunter

Enrollment

1,053

Participants

Timeline

Start Date

November 20, 2014

Primary Completion Date

April 23, 2015

Study Completion Date

September 22, 2015

Conditions

Infections, StreptococcalStreptococcal Infections

Interventions

BIOLOGICAL

GBS Vaccine

Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus

BIOLOGICAL

GBS Vaccine

Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus

Trial Locations (9)

GSK Investigational Site, Leuven

GSK Investigational Site, Ghent

GSK Investigational Site, Baltimore

GSK Investigational Site, Stevensville

GSK Investigational Site, Hradec Králové

GSK Investigational Site, Lenexa

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Redding

GSK Investigational Site, Antwerp